• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2014 Fiscal Year Final Research Report

Development of novel immunotherapy targetimg immune checkpoint blockade for recurrent breast cancer

Research Project

  • PDF
Project/Area Number 24591907
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General surgery
Research InstitutionYamaguchi University

Principal Investigator

YAMAMOTO Shigeru  山口大学, 医学(系)研究科(研究院), 講師 (30289178)

Co-Investigator(Kenkyū-buntansha) YOSHIMURA Kiyoshi  独立行政法人国立がん研究センター, 早期・探索臨床研究センター, 免疫療法開発分野分野長 (30346564)
Project Period (FY) 2012-04-01 – 2015-03-31
Keywords乳癌 / PD-L1 / B7-H3
Outline of Final Research Achievements

1.Programmed death 1 (PD-1) is a co-inhibitory receptor in the immunoglobulin superfamily, and functions as a negative regulator of the immune system. We immunohistochemically investigated the expression of PD-1 and PD-L1 in breast cancer cells and assessed the correlation between the prognosis and clinicopathological factors. Expression of PD-L1 is associated with poor prognosis in HER2-positive breast cancer. 2.B7-H3 belongs to the B7 superfamily of immune regulatory ligands and plays an importantrole in the adaptive immune response of co-inhibitory/stimulatory factors in regulating T cells.We immunohistochemically investigated the presence of B7-H3 and forkhead box P3 (Foxp3)-positive Tregs in pathological specimens from 90 patients with breast cancer.B7-H3 and Foxp3 can be regarded as
markers of poor prognosis in breast cancer. These expressions were not correlated, suggesting that B7-H3 expression plays an independent role in tumor immune evasion, regardless of Tregs.

Free Research Field

乳腺外科学

URL: 

Published: 2016-06-03  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi